NCT03162224: A reported trial by MedImmune LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03162224 |
|---|---|
| Title | A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 26, 2017 |
| Completion date | March 19, 2021 |
| Required reporting date | March 19, 2022, midnight |
| Actual reporting date | March 18, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |